Astria Corp (ATXS) - Long-Term Debt to Capital Coefficient
This market valuation chart for Astria Therapeutics (ATXS) illustrates the price action of an asset valued at 0.01. Astria Therapeutics is collaborating with research centers to test treatments for immune pathologies. The business is currently focusing on developing therapies for rare diseases, anticipating profits upon receiving licenses, while the diversification of contractors ensures the uninterrupted delivery of components for medical tests.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_ATXS_-_Astria-Therapeutics_-_Long-Term-Debt-to-Capital "ATXS: Astria Therapeutics, Inc. Long-Term Debt to Capital 07/04/2022 - 02/07/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Astria Therapeutics (ATXS)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Astria Therapeutics|ATXS - Long-Term Debt to Capital|Short-Term Debt to Capital astriatx.com|ATXS - Company Total Debt|Debt to Net Assets Ratio Astria Therapeutics, Inc.|ATXS - Company Long-Term Debts|Short-Term Debt Volume Astria Therapeutics|Quick Liquidity Indicator astriatx.com
- net income and valuation ratios data:
General company analysis:Astria Therapeutics Inc - ATXS
By focusing on the development of a single orphan drug without large-scale mergers, Astria Therapeutics (ATXS) minimizes its debt load. An analysis of the ratio between long-term borrowed capital and equity allows for an assessment of the company's dependence on external loans with maturities exceeding one year, determining balance sheet stability and the business's ability to fund clinical trials through its own equity without the risk of cash flow gaps.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|Septerna Corp - Long-Term Debt to Capital|PVLA - Long-Term Debt to Capital|Savara Inc. (SVRA) - Long-Term Debt to Equity|RIGL - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio ANAB|ENGN (enGene Holdings Inc) - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity RAPT Therapeutics, Inc. (RAPT)|JBIO (aerovatetx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ACRS (Aclaris Therapeutics)|Ratio of Long-Term Indebtedness to Capital kyvernatx.com (KYTX)|Tiziana Life Sciences Ltd - Long-Term Debt to Capital|CABA - Long-Term Debt to Capital|VTYX (Ventyx Bio) - Long-Term Debt to Equity Ratio|Theratechnologies, Inc - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio AVTX|ELDN (eledon.com) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital AGEN|CLYM (Climb Bio Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ZURA (Zura Bio Limited)|aTyr Pharmaceuticals (ATYR) - Long-Term Liabilities to Capital|ADAG - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient IMA (ImageneBio Inc)|STTK: Long-Term Debt to Capital|Equillium (EQ) - Long-Term Debt to Capital|Long-Term Debt to Equity Connect Biopharma Holdings|Immunic Inc - Long-Term Liabilities to Equity|Long-Term Debt to Capital ATRA|IFRX - Long-Term Liabilities to Capital|X4 Pharmaceuticals, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Adicet Bio Inc. ACET|CELU: Long-Term Debt to Equity Ratio|INmune Bio Corporation - Long-Term Loans to Capital Ratio|BRNS: Long-Term Debt to Capital|KZR - Ratio of Long-Term Indebtedness to Capital|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Akari Therapeutics PLC (AKTX)|Long-Term Debt to Equity Enlivex Therapeutics (ENLV)|Ratio of Long-Term Indebtedness to Capital q32bio.com|Long-Term Debt to Capital GOVX (GeoVax Labs, Inc.)|Long-Term Debt to Capital edesabiotech.com EDSA|IBIO: Long-Term Debt to Equity Ratio|Carisma Therapeutics - Long-Term Loans to Capital Ratio|XTLB (XTL Biopharmaceuticals, Ltd.) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Ratio BOLT|Long-Term Debt to Equity HCW Biologics, Inc.|Aptevo (APVO) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity AIM ImmunoTech (AIM)|ADTX: Long-Term Liabilities to Equity|Long-Term Debt to Capital GRI (GRI Bio Corp)|Long-Term Debt to Capital Coefficient XRTX|Vyome Holdings Inc - Long-Term Debt to Capital|REVB - Long-Term Debt to Capital|Indaptus Therapeutics, Inc. (INDP) - Long-Term Debt to Equity|Scinai Immunotherapeutics Ltd - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity CalciMedica Inc|Long-Term Debt to Equity Ratio Affimed Therapeutics (AFMD)|Long-Term Debt to Capital ALLK|Long-Term Debt to Capital hookipapharma.com (HOOK)|IGM Biosciences - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ITOS|Ocean Bio - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital TC BioPharm Ltd TCBP|Third Harmonic Bio (THRD) - Long-Term Debt to Equity